Eris Lifesciences Limited reaffirmed earnings guidance for the full year of fiscal 2024. Overall, the company reaffirmed financial year '24 guidance of revenue INR 20,000 million to INR 21,000 million, EBITDA of INR 7,000 million to INR 7,100 million and profit after tax of INR 4,100 million to INR 4,150 million.